Physiological Mechanisms Regulating Hydrochloric Acid Secretion
Hydrochloric acid in the stomach is produced by parietal cells. Their stimulation involves several cellular elements and receptors:
- Parietal cell: secretes HCl at the final step.
- ECL cells (enterochromaffin-like cells): release histamine, which acts on $H_2$ histamine receptors on the parietal cell via the adenylate cyclase pathway (cAMP).
- Antral G cells: produce gastrin, which triggers the intracellular calcium pathway ($Ca^{2+}$).
- Vagus nerve ($N. Vagus$): provides parasympathetic stimulation through direct activation of parietal cell $M_3$ muscarinic receptors, also triggering the calcium pathway.
All intracellular signaling pathways converge on the activation of $H^+/K^+-ATPase$ (the proton pump). This enzyme transports hydrogen ions ($H^+$) into the gastric lumen in exchange for potassium ($K^+$), coupled with the efflux of chloride ions ($Cl^-$).
Pharmacological Map: Sites of Action
Pharmacological agents target various components of gastric acid regulation:
- Anticholinergics: pirenzepine blocks $M_1$ receptors at the level of ganglia and ECL cells, while atropine blocks $M_3$ receptors directly on the parietal cell.
- $H_2$ histamine receptor blockers: drugs such as ranitidine and famotidine act as competitive histamine antagonists.
- Gastrin antagonists: proglumide blocks gastrin receptors.
- Prostaglandin analogues: misoprostol stimulates prostaglandin receptors, suppressing cAMP synthesis and acid secretion.
- Proton pump inhibitors (PPIs): omeprazole blocks $H^+/K^+-ATPase$ activity, providing the most potent antisecretory effect at the final step.
Non-Selective Anticholinergics and the Atropine Group
Non-selective agents reduce hydrochloric acid secretion by blocking $M_3$ receptors. The main limitation of this group is their low target selectivity.
Due to atropine-like systemic side effects, these agents are rarely used for peptic ulcer disease. Systemic manifestations include:
- dry mouth (xerostomia);
- mydriasis (pupillary dilation);
- cycloplegia (paralysis of accommodation);
- tachycardia.
Selective M1 Anticholinergics (Pirenzepine)
Selective blockers lack many of the drawbacks of non-selective analogues due to their targeted action on $M_1$ muscarinic receptors located on intramural ganglia, ECL cells, and G cells.
Pirenzepine effect cascade:
- Blockade of $M_1$ receptors.
- Decreased release of histamine from ECL cells and gastrin from G cells.
- Lack of stimulation at corresponding parietal cell receptors.
- Secondary suppression of HCl secretion.
Because the drug poorly crosses tissue barriers (including the blood-brain barrier), systemic side effects are virtually absent. The only common local manifestation remains dry mouth.